



AMENDMENT

IN THE SPECIFICATION:

The title should be amended as follows:

NOVEL OPHTHALMOLOGIC ~~OPHTHALMOLOGIC~~ USES OF PROTEIN C

Paragraph beginning at line 8 of page 1 has been amended as follows:

The present invention relates generally to the fields of ophthalmology, ~~ophthalmology~~, ocular pharmacology and protein chemistry. More specifically, the present invention relates to novel ophthalmologic ~~ophthalmologic~~ uses of Protein C.

Paragraph beginning at line 22 of page 14 has been amended as follows:

The use of Protein C to improve retinal survival is illustrated by the following example. Subretinal macular hemorrhages are created using a Nd:YAG laser focused on pre-formed retinal blebs. Using a pars plana vitrectomy approach, a 20-33 gauge glass micropipette is used to infuse Protein C into the subretinal space for about 2-12 minutes at a rate of about 5 to about 20 microliters per minute. The total dose ranges from ~~form~~ about 0.31 micrograms to about 2.5 micrograms. A one hour period ~~period~~ allows for fibrin prophylaxis and fibrinolysis. The clot is then evacuated using a glass micropipette connected to suction at a rate of 97 to 200 microliters per minute. The animals are sacrificed and enucleated and treated. Control eyes are prepared for histology to assess the retinal architecture. Retinal section photomicrographs are graded in a masked fashion by an ophthalmic ~~ophthalmic~~ pathologist.

Paragraph beginning at line 14 of page 15 has been amended as follows:

The present invention also encompasses the use of Protein C to reduce inflammatory states in the eye, i.e., decreasing conjunctival and iris vascular engorgement and anterior chamber cell and flare. This anti-inflammatory effect of Protein C is useful in such ophthalmic ~~ophthalmic~~ conditions as immediate post-operative or post-traumatic states or in those patient who have undergone glaucoma filtration surgery, in patients with inflammatory glaucoma or to reduce the risk of corneal transplant rejection.